Erratum: The inhibitory effects of HYDAMTIQ, a novel PARP inhibitor, on growth in human tumor cell lines with defective DNA damage response pathways (Oncology Research 25:9 (1441-1451) DOI: 10.3727/096504017X14926854178616)